The invention relates to an improved process for the preparAT1on of 2-butyl-4-chloro-l-[[(2"-(lH-tetrazole-5-yl)[1,1-biphenyl]-4-yl]methyl]-lH-imidazole-5-methanol or its pharmaceutically acceptable potassium salt, which comprises reacting bromo OTBN with BCFI or its salts in absence of a base and phase transfer catalyst to get a cyano aldehyde, the cyano aldehyde was reduced with sodium borohydride to give cyano alcohol followed by tetrazole formAT1on by reacting cyano alcohol with inorganic azide in presence amine or salt thereof to give 2-butyl-4-chloro-l-[[(2"-(lH-tetrazole-5-yl)[1,1"-biphenyl]-4-yl]methyl]-lH-imidazole-5-methanol and finally converting 2-butyl-4-chloro-l-[[(2"-(lH-tetrazole-5-yl)[1,1-biphenyl]-4-yl]methyl]-lH-imidazole-5-methanol to its pharmaceutically acceptable potassium salt by treAT1ng it with potassium hydroxide.[IN-MUM-2008-00191A]
